Aging is a natural part of every human being. Its visible effects on skin are a concern which a lot of people like to address in their day-to-day routine.
To counteract the signs of aging Evonik offers a new solution – TEGO® Arjuna S. It is a standardized solution of pentacyclic triterpenes from the bark of the arjun tree. This plant has a long history of use in India's Ayurvedic medicine. Based on this tradition and knowledge Evonik developed an active ingredient with broad activity to combat the signs and effects of hormonal aging. Beside the shown efficacy TEGO® Arjuna S has the advantage to be SFDA accepted.
In vitro DNA chip, gene and protein studies on different cell types have proven that TEGO® Arjuna S is able to induce important growth factors like VEGF. Furthermore, it up-regulates markers related to increased sebum production (FGFR2, FGF2).
An in vivo study on people with mature skin verified the in vitro results showing that TEGO® Arjuna S contributes to an improved skin blood microcirculation leading to a better skin nutrient supply.Additional in vivo results have proven that it strengthens the extracellular matrix leading to improved dermal density and resiliency. By strengthening the skin barrier and inducing skin sebum production it reduces the signs of dry skin and protects the skin from external challenges. Summarizing these benefits TEGO® Arjuna S helps easing aging without hormonal influence on such as estrogens like other active ingredients used for this kind of application.
As more and more consumer products targeted for special age groups can be seen on the market TEGO® Arjuna S is an interesting active for the various application types for mature respectively menopausal skin. Due to its broad activity TEGO® Arjuna S is as well suitable for product focusing on treatments of dark circles or scalp care applications.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.